Top Page
Alpha Tau Medical Ltd
(NASDAQ:DRTS)
Alpha Tau Medical Ltd (DRTS) vs. SPDR S&P 500 ETF (SPY)
Alpha Tau Medical Ltd Business Overview & Revenue Model
Alpha Tau Medical Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -1.10M | -1.07M | -979.00K | -776.00K | -86.00K |
| EBITDA | -34.34M | -30.30M | -28.03M | -32.74M | -13.21M | -9.16M |
| Net Income | -39.97M | -31.75M | -29.16M | -33.76M | -27.27M | -8.88M |
Balance Sheet | ||||||
| Total Assets | 104.69M | 86.20M | 107.39M | 120.15M | 42.22M | 52.99M |
| Cash, Cash Equivalents and Short-Term Investments | 72.21M | 59.60M | 81.79M | 104.53M | 31.32M | 46.02M |
| Total Debt | 13.50M | 12.54M | 13.28M | 5.19M | 53.96M | 53.96M |
| Total Liabilities | 27.11M | 23.54M | 22.91M | 14.49M | 76.99M | 61.42M |
| Stockholders Equity | 77.58M | 62.67M | 84.47M | 105.66M | -34.78M | -8.43M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -22.02M | -24.36M | -24.78M | -14.74M | -11.02M |
| Operating Cash Flow | 0.00 | -19.78M | -17.96M | -23.88M | -11.81M | -7.25M |
| Investing Cash Flow | 0.00 | 20.77M | 18.68M | -89.94M | 19.27M | -7.82M |
| Financing Cash Flow | 0.00 | 25.00K | 5.30M | 96.91M | 111.00K | 29.32M |
Alpha Tau Medical Ltd Technical Analysis
Alpha Tau Medical Ltd Risk Analysis
Alpha Tau Medical Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $1.33B | -13.62 | -107.79% | ― | -52.08% | -69.35% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $648.01M | -14.57 | -54.38% | ― | ― | -22.82% | |
48 Neutral | $420.23M | -12.34 | -43.71% | ― | ― | 80.95% | |
46 Neutral | $530.62M | -2.69 | -80.69% | ― | ― | 4.97% | |
45 Neutral | $280.74M | -1.70 | -78.24% | ― | ― | -67.41% | |
42 Neutral | $365.14M | -2.98 | -64.26% | ― | ― | -11.41% |
Alpha Tau Medical Ltd Corporate Events
On January 29, 2026, Alpha Tau Medical issued a shareholder letter outlining an intensifying clinical and pre-commercial agenda for 2026, highlighted by five concurrent U.S. trials of its Alpha DaRT therapy in skin, pancreatic, brain and prostate cancers, additional studies in Europe and Israel, and preparations for a large basket trial in the UK. The company expects to complete patient recruitment in its IMPACT pancreatic cancer trial by the end of the first quarter of 2026 with initial data anticipated by year-end, is targeting first results from its U.S. glioblastoma study around the end of 2026, and is awaiting a near-term regulatory decision in Japan on Alpha DaRT for recurrent head and neck cancer that could mark its first commercial approval outside Israel. Alongside ongoing data generation from its pivotal ReSTART skin cancer trial and planned exploration of Alpha DaRT in combination with checkpoint inhibitors for advanced head and neck cancer, Alpha Tau is ramping U.S. manufacturing capacity, advancing a modular PMA submission to the FDA, and building organizational and production infrastructure in the U.S. and Israel, signaling that it is positioning itself for potential commercialization and broader adoption of its platform if upcoming clinical and regulatory milestones are favorable.
The most recent analyst rating on (DRTS) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
On January 6, 2026, Alpha Tau Medical reported final results from its first-in-human pancreatic ductal adenocarcinoma study in Montreal, showing an 81% disease control rate across 32 patients treated with its Alpha DaRT therapy, rising to 87% when excluding the first two low-dose feasibility patients, along with a 22–23% objective response rate and a favorable safety profile. Complementary data from 23 patients demonstrated preservation of key immune and inflammatory markers one month after treatment, including stable neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and a marked reduction in IL-6 levels, suggesting an immune-preserving, less inflammatory radiation profile that could support combination with systemic therapies such as chemotherapy or immunotherapy; these findings reinforce Alpha Tau’s strategic focus on pancreatic cancer, underpin ongoing U.S. and European trials, and may strengthen the company’s positioning as it seeks future regulatory approval for Alpha DaRT in this high-need indication.
The most recent analyst rating on (DRTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
On January 5, 2026, Alpha Tau Medical announced it has submitted the first module of its pre-market approval application to the U.S. Food and Drug Administration for Alpha DaRT in the treatment of recurrent cutaneous squamous cell carcinoma in patients who are not candidates for surgery or standard radiation and lack curative systemic options. The FDA has allowed the company to use a modular PMA approach, enabling staged review of non-clinical and other data, and the initial module focuses on comprehensive non-clinical documentation; this step, taken in parallel with the ongoing multi-center ReSTART pivotal study that is expected to complete patient recruitment in the first quarter of 2026, marks a key regulatory milestone that could help streamline U.S. review and potentially strengthen Alpha Tau’s position in the skin cancer treatment market if future modules and clinical results support approval.
The most recent analyst rating on (DRTS) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
On December 18, 2025, Alpha Tau Medical Ltd. announced that CEO Uzi Sofer and CFO Raphi Levy will deliver a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference in San Francisco on January 15, 2026, and will hold one-on-one meetings with institutional investors during the event. The presentation is expected to highlight the company’s recent achievements and outline upcoming data milestones for its Alpha DaRT solid-tumor therapy, signaling an effort to raise Alpha Tau’s visibility with global healthcare investors and potentially strengthen its position within the oncology therapeutics space as it advances toward further clinical and commercial development.
The most recent analyst rating on (DRTS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
On December 9, 2025, Alpha Tau Medical Ltd. announced the successful treatment of the first patient in its U.S. trial for recurrent glioblastoma using its Alpha DaRT technology at The Ohio State University. This pilot study is part of Alpha Tau’s strategy to address high unmet needs in cancer treatment, supported by FDA’s Breakthrough Device Designation, and marks a significant milestone in neuro-oncology by offering a novel therapeutic approach for a highly resistant cancer.
The most recent analyst rating on (DRTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
On December 4, 2025, Alpha Tau Medical Ltd. announced the acceptance of two abstracts related to its Alpha DaRT technology for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium. These abstracts, focusing on pancreatic cancer, highlight the company’s ongoing clinical trials, including a multi-center study in the U.S. that began in September 2025. This development underscores Alpha Tau’s commitment to addressing high unmet needs in cancer treatment, particularly for pancreatic cancer patients who often face limited treatment options.
The most recent analyst rating on (DRTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
On December 2, 2025, Alpha Tau Medical Ltd. announced that it received FDA approval to initiate a pilot study for treating patients with locally recurrent prostate cancer using its Alpha DaRT technology. This marks the company’s fifth active U.S. IDE, expanding its reach in the U.S. market. The trial will enroll up to 12 U.S. patients and aims to evaluate the safety and efficacy of Alpha DaRT as a local salvage therapy, offering an alternative to current treatments for recurrent prostate cancer. This development could significantly impact Alpha Tau’s operations and industry positioning, as it addresses a critical need for new treatments in the prostate cancer segment.
The most recent analyst rating on (DRTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
On November 20, 2025, Alpha Tau Medical Ltd. announced its third quarter 2025 financial results and provided a corporate update. The company highlighted significant progress, including the commencement of Alpha DaRT pancreatic cancer treatments in a U.S. multi-center pilot study and the receipt of a radioactive material license for its New Hampshire facility, positioning it for commercial readiness. Alpha Tau also reported a cash balance of $75.9 million, supporting ongoing clinical advancements and commercial preparations. The company aims to achieve several milestones in the coming months, such as completing patient recruitment in the U.S. ReSTART trial and receiving a response from Japan’s PMDA regarding marketing authorization for treating recurrent head and neck cancer.
The most recent analyst rating on (DRTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.